1.35
-0.04(-2.88%)
Currency In USD
| Previous Close | 1.39 |
| Open | 1.37 |
| Day High | 1.39 |
| Day Low | 1.28 |
| 52-Week High | 2.17 |
| 52-Week Low | 0.28 |
| Volume | 2.6M |
| Average Volume | 2.7M |
| Market Cap | 490.59M |
| PE | -4.22 |
| EPS | -0.32 |
| Moving Average 50 Days | 1.15 |
| Moving Average 200 Days | 0.81 |
| Change | -0.04 |
If you invested $1000 in Lexicon Pharmaceuticals, Inc. (LXRX) 10 years ago, it would be worth $122.5 as of October 01, 2025 at a share price of $1.35. Whereas If you bought $1000 worth of Lexicon Pharmaceuticals, Inc. (LXRX) shares 5 years ago, it would be worth $944.06 as of October 01, 2025 at a share price of $1.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
GlobeNewswire Inc.
Sep 22, 2025 8:00 PM GMT
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA fee
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b studyTHE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
GlobeNewswire Inc.
Sep 11, 2025 12:30 PM GMT
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annual Pain Summ